{"denoms":[{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}],"units":"Participants"}],"description":"The primary efficacy endpoint of ORR in patients with AML who received INCB053914 plus azacitidine in Part 4 was not performed due to limited enrollment as a result of early study termination.","groups":[{"description":"Combination Treatment Group B INCB053914 50 mg BID + Azacitidine","id":"OG000","title":"Part 4: INCB053914 50 mg BID + Azacitidine"},{"description":"Combination Treatment Group B: B053914 80 mg BID + Azactidine","id":"OG001","title":"Part 4: INB053914 80 mg BID + Azactidine"}],"populationDescription":"Part 4 was not opened for enrollment.","reportingStatus":"POSTED","timeFrame":"Approximately 6 months","title":"Part 4 Only : Determination of the Efficacy of INCB053914 in Combination With Azacitidine in Subjects With Newly Diagnosed AML Who Are 65 Years or Older and Unfit for Intensive Chemotherapy Based on ORR","type":"PRIMARY"}